宏利香港次季核心盈利按年增5%至14亿元
宏利香港公布,上半年核心盈利按年增长8%至29亿元,其中次季增长5%至14亿元。上半年年度化保费等值销售额按年增长5%至30亿元,次季按年倒退8%至14亿元。宏利香港及澳门首席行政总监戴明钧於电话会议上表示,若撇除内地旅客之影响,次季年度化保费等值销售额实按年增长14%。
上半年宏利香港新业务价值按年增长4%至17亿元,次季倒退13%至8亿元。代理人数目於上半年增加13%至10,008人。戴明钧表示,4月及5月保险销售持续倒退,主要由於肺炎疫情及隔离措施对销售造成影响,6月销售则有大幅回升。
至於部份本港官员被美国制裁,会否影响宏利业务及其客户,戴明钧表示,公司正密切注意相关事件,暂未能作出评论。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.